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ABSTRACT 
A  simple,  selective,  precise,  specific  and  reproducible  indicating  high-performance  thin  layer  chromatographic  method  for  routine  analysis  of 
esomeperazole (ESO) and domperidone (DOM) as bulk drugs and in tablet formulation has been developed and validated. Aluminium foil TLC plates 
precoated with silica gel 60F 254 were used as stationary phase and toluene: ethyl acetate: methanol (2:7:0.5 v/v/v) as mobile phase. A compact band 
(Rf  values 0.54±0.01 and 0.33±0.01) was obtained for esomeprazole and domperidone respectively. Linear regression analysis revealed a good linear 
relationship (r
2 =0.9972±0.01) between peak area and concentration in the range 200-600ng/spot for esomeperazole and (r
2 =0.9985±0.01) in the 
range 400-1200ng/spot for domperidone.  The mean values ± SD of the slope and intercept were 12.967±0.033 and 1513.4±1.20 respectively for 
esomeperazole and 8.192±0.035 and 1664±0.62 respectively for domperidone. Densitometric analysis was performed in absorbance mode at 286 nm 
selected  as  isobestic  point.  Review  of  literature  reveals  that  few  HPLC,  LC-MS  and  HPTLC  methods  have  been  reported  for  estimation  of 
esomeprazole and domperidone in single and in combination with other drugs, but no HPTLC method is reported so far for simultaneous estimation 
of  this  combination.  The  limits  of  detection  and  quantitation  were  50  and  80ng/spot  respectively  for  esomeperazole  and  80  and  100ng/spot 
respectively  for domperidone. The  method  was validated  for  precision, recovery, and robustness. Statistical analysis proved the  method enables 
repeatable, selective, and accurate analysis of the drug. It can be used for identification and quantitative analysis of esomeperazole and domperidone 
in the bulk drugs and in tablet formulations. 
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INTRODUCTION 
Esomeperazole  (ESO)  S-bis  (5-methoxy-2-[(S)-[(4-
methoxy-3,5-dimethyl-2  pyridinyl)  methyl]  sulfinyl-1]-
1H-benzimidazole-1-yl) magnesium trihydrate is a proton 
pump inhibitor that suppresses gastric acid secretion by 
specific  inhibition  of  the  H+/K+-ATPase  in  the  gastric 
parietal cell. The S- and R- isomers of omeprazole are 
protonated and converted in the acidic compartment of the 
parietal  cell  forming  the  active  inhibitor,  the  achiral 
sulphenamidey
1,2.  Domperidone  (DOM)  5-chloro-1-[-1-
[3-(2,3-dihydro-2-oxo-1H-benzimadozol-1-yl)propyl]-4-
piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one  is  a 
synthetic benzimidazole compound that acts as dopamine 
antagonist with antiemetic properties. It is also used as 
prokinetic  agent  for  treatment  of  upper  gastrointestinal 
motility disorders
3-5. Review of literature reveals that few 
HPLC, LC-MS and HPTLC methods have been reported 
for estimation of esomeprazole and domperidone in single 
and  in  combination  with  other  drugs,  but  no  HPTLC 
method is reported so far for simultaneous estimation of 
this combination
6-12. The objective of present work was to 
develop a simple, accurate and reproducible procedure for 
determination  of  esomeprazole  and  domperidone  by 
HPTLC as bulk and in tablet dosage form. 
 
MATERIALS AND METHODS 
Chemicals and Reagents 
Esomeperazole  was  supplied  as  gift  sample  by  Torrent 
pharmaceutical ltd. Ahemedabad and Domperidone was 
gift sample by Vamsi labs ltd. Solapur. All chemicals and 
reagents  used  were  of  analytical  grade  and  were 
purchased from Merk Chemicals, Mumbai, India. Tablets 
containing 20mg of ESO and 30mg of DOM (ESOZ-D-
20) was purchased from local market. 
HPTLC Instrumentation and Conditions  
Chromatography was performed on 20 cm × 20 cm on 
aluminium  foil  plates  precoated  with  0.2-mm  layers  of 
silica gel 60F254 (E. Merck, Germany). Before use the 
plates  were  prewashed  by  development  with  methanol 
then dried in the current of dry air and activated at 110 °C 
for 5 min. Samples were applied as bands 6 mm wide, 6 
mm  apart.  Camag  Linomat  V  semiautomatic  sample   
applicator,  Hamilton  syringe  (100  µl),  Camag  TLC 
Scanner-3  with  CATS  4  software,  Camag  twin-  trough 
chamber (20×10 cm) and Remi centrifuge (Model C30) 
were used for the present study. The mobile phase was 
toluene:  ethyl  acetate:  methanol  (2:7:0.5).  Linear 
ascending development was performed in a twin-trough 
glass  chamber  previously  saturated  with  mobile  phase 
vapour  for  30  min  at  room  temperature  and  relative 
humidity  60±5%.  Ten  μl  of  standard  solutions  of 
esomeprazole (200 µg/ml) and domperidone (600 µg/ml) 
were  applied  on  pre-washed  and  activated  plate  under 
nitrogen stream using semiautomatic spotter. They were 
developed at constant temperature in a Camag twin trough 
chamber previously saturated for 20 min with mixture of 
toluene  ethyl acetate  methanol (2:7:0.5) as mobile phase. 
The plates were removed from the chamber and dried in 
air. Densitometric measurements were performed at 286 
nm in reflectance mode with Camag TLC Scanner 3 using 
CATS  4  software  incorporating  track  optimization 
position using deuterium lamp as source of radiation. The 
slit dimensions were 6 mm × 0.45 mm were shown in 
figure 1.
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Figure 1: Densitogram of standard esomeprazole (4000 ng/spot) and 
domperidone. (6000 ng/spot); (Rf, 0.54±0.01 for esomeprazole and 
Rf, 0.33±0.01 for domperidone); 
Mobile phase; toluene  ethyl acetate  methanol (2:7:0.5) 
 
Calibration 
A  stock  solution  containing  100  μg/ml  ESO  and  200 
μg/ml DOM was prepared in methanol. Different volumes 
of  this  solution  were  applied  to  the  plate  resulting  in 
application  of  200-  600  ng/spot  for  ESO  and  400-
1200ng/spot  for  DOM  to  the  plate.  Each  concentration 
was applied seven times to the plate and the plate was 
developed  as  described  above.  Peak  areas  were  plotted 
against  corresponding  concentrations  to  furnish  the 
calibration plot. The overlain UV spectrum which were 
shown in figure 2. 
 
 
Figure 2: Overlain UV spectrum for esomeprazole and domperidone 
 
Method Validation  
Precision 
Repeatability of sample application and measurement of 
peak  area  were  assessed  by  chromatography  of  six 
replicates of the same concentration (600 ng /spot ESO 
and 1200ng/spot DOM).Intra-day and inter-day variation 
for  determination  of  ESO  (200,  400,  600  ng/spot).and 
DOM  was  measured  at  concentrations  (400,  800,  1200 
ng/spot).
 13-15 
Robustness 
Small  changes  in  the  chromatographic  conditions  were 
introduced and the effects on the results were examined. 
Small variations in mobile phase composition (±0.1 %), 
amount of mobile phase (±5 %), time from spotting to 
chromatography (±20 min) and scanning time (±20 min). 
The  %  RSD  of  peak  area  for  each  parameter  was 
calculated. 
Limits of Detection and Quantitation 
To  determine  the  limits  of  detection  and  quantitation, 
concentrations in the lower part of the linear range of the 
calibration plot were used. Stock solution of ESO (100 
μg/ml) and DOM (200 μg/ml) was prepared and applied 
in triplicates in different volumes in the range of 10 to 
200ng.  The  time  from  spotting  to  chromatography  and 
time from chromatography to scan was varied at 0 and 20 
min. 
Specificity 
The specificity of the method was determined by analysis 
of  drug  standards  and  samples.  The  band  for  ESO  and 
DOM in the sample was identified by comparing the R 
value and F spectrum of the band with those of the band 
from a standard. The peak purity of ESO and DOM was 
assessed by comparing spectra acquired at three different 
positions on the peak. 
Recovery 
Recovery studies were carried out by applying the method 
to drug sample to which known amount of esomeprazole 
and domperidone corresponding to 80, 100 and 120 % of 
label claim had been added (standard addition method). 
At  each  level  of  the  amount,  six  determinations  were 
performed and the results obtained were compared with 
expected results. 
Analysis of the Marketed Formulation 
To determine the ESO & DOM contents of conventional 
tablets, twenty tablets were weighed and powdered in a 
glass  mortar.  An  amount  of  powder  equivalent  to  the 
average  weight  of  the  one  tablet  ESO  &  DOM  was 
transferred  to  a  50  ml  volumetric  flask,  extracted  with 
methanol. The solution was centrifuged for 15minutes at 
600  RPM.  The  resulting  solution  was  filtered  through 
whatman filter paper no.41 and residue was washed with 
methanol and volume was adjusted 250ml with the same 
solvent  to  obtained  final  concentration  of  200µg/ml  of 
ESO  &  600µg/ml  of  DOM.  The  two  drugs  were 
satisfactorily  resolved  with  Rf  values  0.55±0.01  and 
0.34±0.01  for  esomeprazole  and  domperidone 
respectively. 
 
RESULTS AND DISCUSSION 
HPTLC Method Optimisation and Validation 
A  solvent  system  that  would  give  dense  and  compact 
spots  with  appropriate  and  significantly  different  Rf 
values was desired for quantification of esomeprazole and 
domperidone  in  pharmaceutical  formulations.  Various 
solvent  systems  like  chloroform  methanol,  chloroform 
toluene acetic acid, benzene methanol toluene were tried 
to  separate  and  resolve  spots  of  esomeprazole  and 
domperidone from their impurities and other excipients of 
formulations.  The  mixture  of  toluene    ethyl  acetate  
methanol  (2:7:0.5)  could  resolve  esomeprazole  and 
domperidone with better peak shape. The two drugs were 
satisfactorily  resolved  with  Rf  values  0.54±0.01  and 
0.33±0.01  for  esomeprazole  and  domperidone 
respectively. 
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Validation 
Linearity and range 
The linear regression data for calibration curves (n = 6) 
showed  good  linear  relationship  over  a  concentration 
range of 200-600 ng/spot for esomeprazole and 400-1200 
ng/spot for domperidone shown in Table 1-4. 
 
Table 1: Linearity and range of esomeprazole 
Sr. No.  Concentration (ng/spot)  Area (AU)* 
1  200  4182 
2  300  5407 
3  400  6604 
4  500  7878 
5  600  9430 
*n=6 
 
Table 2: Linear regression data for calibration curve of 
esomeprazole 
Parameters  Data* 
Linearity range  200-600 ng/spot 
r
2  0.9972 
Slope ± SD  12.967±0.033 
Intercept ± SD  1513.4 ± 1.20 
*n=6 
 
Table 3: Calibration linearity and range of domperidone 
Sr. No.  Concentration (ng/spot)  Area (AU)* 
1  400  4934 
2  600  6686 
3  800  8119 
4  1000  9760 
5  1200  11589 
*n=6 
 
Table 4: Linear regression data for calibration curve of 
domperidone 
Parameters  Data* 
Linearity range  400-1200 ng/spot 
r
2  0.9985 
Slope ± SD  8.192 ± 0.035 
Intercept ± SD  1664 ± 0.62 
*n = 6 
 
Precision 
Tables  5-8  shown  that  intraday  and  interday  relative 
standard deviations are found in the range 0.21-0.54 % 
and 0.18-0.29% for esomeprazole and 0.36-0.53 % and 
0.33-0.58  %  for  domperidone.  The  smaller  values  of 
intraday  and  interday  variation  in  the  analysis  indicate 
that the method is precise. 
 
Table 5: Intraday precision of esomeprazole 
Concentration (ng)  Average Area  SD  % RSD* 
200  4190  22.91  0.54 
400  6608  14.50  0.21 
600  9443  24.54  0.25 
*n = 3 
 
Table 6: Inter day precision of esomeprazole 
Concentration (ng)  Average Area  SD  % RSD* 
200  4181  12.34  0.29 
400  6606  12.05  0.18 
600  9439  19.67  0.20 
*n = 3 
 
Table 7: Intra day precision of domperidone 
Concentration (ng)  Average Area  SD  % RSD* 
400  4918  23.02  0.46 
800  8133  43.46  0.53 
1200  11584  42.15  0.36 
*n = 3 
 
Table 8: Inter day precision of domperidone 
Concentration (ng)  Average Area  SD  % RSD* 
400  4948  17.61  0.35 
800  8176  48.04  0.58 
1200  11605  39.06  0.33 
*n = 3 
Robustness 
When the standard deviation of peak area was calculated 
for each change of conditions RSD was found to be less 
than 2%. These low RSD values given in Table 9 & 10 
indicated the method is robust. 
 
Table 9: Robustness of esomeprazole 
Parameters  % RSD 
Mobile phase composition (± 0.1 ml)  1.47 
Amount of mobile phase (± 0.5 %)  1.32 
Time from spotting to chromatography (± 20 min)  0.54 
Time from chromatography to scanning (± 20 min)  1.01 
*n = 3 
 
Table 10: Robustness of domperidone 
Parameters  % RSD 
Mobile phase composition (± 0.1 ml)  1.14 
Amount of mobile phase (± 0.5 %)  1.22 
Time from spotting to chromatography (± 20 min)  0.36 
Time from chromatography to scanning (± 20 min)  0.92 
*n = 3 
Recovery 
When the method was used for extraction and subsequent 
analysis  of  ESO  &  DOM  from  pharmaceutical  dosage 
forms after spiking with 80, 100, and 120% of additional 
drug, recovery was 98.51±0.23% for ESO and 99.01±0.15 
% for DOM were shown in Table 11. 
 
Table 11: Recovery of esomeprazole and domperidone 
Label claim 
(mg/tablet) 
Amount added 
(%) 
Total amount 
added (mg) 
Amount recovered 
(mg) 
% Recovery ± 
SD* 
% RSD 
Esomeprazole 
 
20 
80  36  35.7  98.58±0.27  0.28 
100  40  39.6  98.25±0.20  0.21 
120  44  43.7  98.70±0.22  0.23 
Domperidone 
 
30 
80  54  53.8  99.16±0.25  0.25 
100  60  59.8  99.00±0.21  0.21 
120  66  65.7  98.87±0.23  0.23 
*n=6 
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Limits of Detection and Quantitation 
The  limit  of  detection  was  found  to  be  50  ng/spot  for 
esomeprazole and 80 ng/spot for domperidone and limit 
of  quantitation  was  found  to  be  80  ng/spot  for 
esomeprazole  and  100  ng/spot  for  domperidone.  This 
indicates the sensitivity of the method is adequate were 
shown in Table 12. 
 
Table 12: LOD and LOQ for esomeprazole and domperidone 
Drug  LOD  LOQ 
Esomeprazole  50 ng/spot  80 ng/spot 
Domperidone  80 ng/spot  100 ng/spot 
 
Specificity 
It was observed that excipients present in formulation did 
not interfere with peaks of esomeprazole (Rf, 0.55±0.01) 
and domperidone (Rf, 0.34±0.01) shown in figure 3. 
 
 
Figure 3: Densitogram of marketed formulation ESOZ-D-20 
containing 20 mg of esomeprazole and 30 mg ofdomperidone;  
(Rf, 0.55±0.01 for esomeprazole and Rf, 0.34±0.01 for domperidone) 
 
Assay of marketed formulation 
The  spot  was  resolved  into  two  peaks  in  the 
chromatogram  of  drug  samples,  extracted  from  the 
marketed formulation of Rf, 0.55±0.015 for ESO and Rf, 
0.34±0.01 for DOM. The content of drug was calculated 
from the peak areas recorded. There was no interference 
from the excipients commonly present in the tablets. The 
drug content was found to be 98.62 ± 0.50% and 99.05± 
0.30% for ESO and DOM respectively. The low value of 
RSD indicates the method is suitable for routine analysis 
of ESO and DOM in pharmaceutical dosage forms were 
shown in Table 13. 
 
Table 13: Assay of esomeprazole and domperidone 
Sr. 
No. 
Label claim 
(mg) 
Amount found 
(mg) 
% Drug 
content* 
ESO  DOM  ESO  DOM  ESO  DOM 
1   
20 
 
 
30 
19.82  29.90  98.22  99.03 
2  19.74  29.87  97.47  98.77 
3  19.91  29.93  99.18  99.36 
*n=3 
 
 
 
 
CONCLUSION 
The  developed  HPTLC  proposed  method  is  rapid, 
accurate, precise, specific and reproducible which could 
be  used  as  effective  quality  control  tool  for  routine 
analysis of esomeprazole and domperidone as bulk drugs 
and in tablet formulations without any interference from 
the excipients. 
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